Compare NRP & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRP | DMRA |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2002 | 2020 |
| Metric | NRP | DMRA |
|---|---|---|
| Price | $99.11 | $29.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $43.00 |
| AVG Volume (30 Days) | 37.1K | ★ 801.4K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $216,119,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.28 | ★ N/A |
| Revenue Growth | ★ 54.66 | N/A |
| 52 Week Low | $96.39 | $16.50 |
| 52 Week High | $128.60 | $30.19 |
| Indicator | NRP | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.47 | 70.50 |
| Support Level | N/A | $22.71 |
| Resistance Level | $108.19 | N/A |
| Average True Range (ATR) | 2.85 | 2.42 |
| MACD | 0.03 | 0.91 |
| Stochastic Oscillator | 28.30 | 98.09 |
Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. The majority of the revenue is generated from the Mineral Rights segment. Geographically, the company's business activity of the group functions through the United States.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.